Basic Information
| LncRNA/CircRNA Name | CCAT2 |
| Synonyms | CCAT2, LINC00873, NCCP1 |
| Region | GRCh38_8:127400399-127402150 |
| Ensemble | ENSG00000280997 |
| Refseq | NR_109834 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, RNAi, Western blot, Cell proliferation assay etc. |
| Sample | prostate cancer tissues, cell lines (DU-145, 22RV1, WPMY-1) |
| Expression Pattern | up-regulated |
| Function Description | We found that the expression level of CCAT2 was higher in PCa tissues and cells compared to adjacent non-tumor tissues and normal prostate stromal immortalized cells WPMY-1. We also found that knockdown of CCAT2 could inhibit cell growth, migration, and invasion in vitro. In addition, knockdown of CCAT2 stimulated epithelial-mesenchymal transition (EMT) through abrogating N-cadherin, vimentin expression and intensifing the expression levels of E-cadherin. |
| Pubmed ID | 27558961 |
| Year | 2016 |
| Title | The up-regulation of long non-coding RNA CCAT2 indicates a poor prognosis for prostate cancer and promotes metastasis by affecting epithelial-mesenchymal transition. |
External Links
| Links for CCAT2 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |